El Paso Health
HEALTH PLANS FOR EL PASOANS. BY EL PASOANS.

MEDICAID

MENTAL HEALTH CLINICAL PRACTICE GUIDELINES

Follow up After Hospitalization for Mental Illness

The following guideline provides recommendations for members 6 years of age and older who were hospitalized for treatment of mental illness or intentional self-harm and who had a follow up visit with a mental health practitioner.

A follow up visit with a mental health practitioner within 7 or 30 days after discharge, not to include visits on date of discharge. Any of the following meets criteria:	• Outpatient visit with mental health practitioner • A community mental health center visit with a mental health practitioner • A telehealth or telephone visit with a mental health practitioner • An observation visit with a mental health practitioner • Transitional care management services with a mental health provider • Psychiatric collaborative care management • Electroconvulsive therapy

Follow up care for Children Prescribed ADHD Medication

The following guideline provides recommendations for members 6 to 12 years of age that have been newly prescribed ADD and/or ADHD disorder medications. (Applies if member didn't have any ADHD medications dispensed [new or refill prescriptions] 120 days prior to new prescription start date.)

A follow up visit with a practitioner with prescribing authority within 30 days after the dispensing date for the ADHD medication. Any of the following meets criteria:	• Outpatient visit • Observation visit • Health and behavior assessment/intervention • Community mental health center visit • Telehealth or Telephone visit
At least two follow up visits with any practitioner from 31 to 270 days after the dispensing date for the ADHD medication. Any of the following meets criteria:	• Outpatient visit • Observation visit • Health and behavior assessment/intervention • Community mental health center visit • Telehealth or Telephone visit • E-visit or virtual check-in *(only one of the 2 visits may be an e-visit or virtual check-in)*
ADHD Medications	Dexmethylphenidate, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Methamphetamine, Clonidine, Guanfacine, Dexmethylphenidate-serdexmethylpenidate, Atomoxetine, Viloxazine

These guidelines are based on the HEDIS 2026(MY2026) Performance Measures. Individual patient considerations and advances in medical science may supersede or modify these recommendations